Date: 2016-01-07
Type of information: Development agreement
Compound: CEP-8983 and CEP-9722
Company: Teva Pharmaceutical Industries (Israel) Checkpoint Therapeutics (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: poly ADP ribose polymerase PARP inhibitor/PARP inhibitor.
Disease:
Details: * On January 7, 2016, Teva Pharmaceutical Industries and Checkpoint Therapeutics, a Fortress Biotech Company, announced a license agreement in which Checkpoint will obtain the exclusive worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug, CEP-9722, an oral poly (ADP-ribose) polymerase (PARP) inhibitor in early clinical development for solid tumors. CEP-9722 is a novel, orally active, small molecule selective inhibitor of PARP-1 and PARP-2 enzymes that will be developed by Checkpoint as both a monotherapy and in combination with other anti-cancer agents, including Checkpoint's novel immuno-oncology and checkpoint inhibitor antibodies currently in development.
Financial terms:
Latest news:
